Literature DB >> 12848377

Influence of long term cyclosporine therapy on insulin and its precursors secretion in patients after heart transplantation.

Teresa Zielińska1, Michał Zakliczyński, Marta Szewczyk, Aleksandra Zielińska-Kukla, Jerzy Foremny, Zbigniew Kalarus, Zbigniew Religia, Marian Zembala.   

Abstract

Diabetes mellitus is a very well recognized risk factor for coronary artery disease in non-transplant patients. With the introduction of new immunosuppressive agents in solid organ recipients, there is an interest in medical complications of immunosuppressive therapy. An influence of long-term cyclosporine-A (CyA) therapy on glucose metabolism was analyzed in a group of 122 heart transplant recipients who developed hyperglycemia after heart transplantation. Based on WHO criteria for diagnosis of diabetes two groups were identified: group 1 (102 pts) included pts with impaired glycemic control and group 2 (20 pts) with clinical diabetes. Fasting insulin, proinsulin, C-peptide, HbA1c and cyclosporine-A trough levels were determined 12-18 months post surgery in clinically stable period without transplant rejection. The immunosuppressive treatment in both groups was the same and consisted of cyclosporine A, azathioprine and prednisone. We observed a statistically significant negative correlation between CyA concentration and insulin in both groups, a statistically significant negative correlation between CyA concentration and proinsulin, C-peptide blood level in group 1 and statistically significant positive correlation between CyA and glucose blood level in both groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12848377

Source DB:  PubMed          Journal:  Ann Transplant        ISSN: 1425-9524            Impact factor:   1.530


  1 in total

1.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.

Authors:  Abraham J Wilhelm; Peer de Graaf; Agnes I Veldkamp; Jeroen J W M Janssen; Peter C Huijgens; Eleonora L Swart
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.